MedTrace Logo

Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

NCT01992094 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2680

Last updated 2015-12-10

Study results available
· View outcomes & findings →

Summary

Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.

Conditions

Interventions

BIOLOGICAL

QIVc

Novartis Investigational Quadrivalent Vaccine

BIOLOGICAL

TIV1c

Licensed Influenza Vaccine

BIOLOGICAL

TIV2c

Novartis Investigational Vaccine

Sponsors & Collaborators

  • Novartis Vaccines

    lead INDUSTRY

Principal Investigators

  • Novartis Vaccines · Novartis Vaccines

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01992094 on ClinicalTrials.gov